SMS Pharma surges 20% on successful inspection of Telangana unit by PMDA
The stock surged 20% to Rs 87.60 on BSE in intra-day trade on back of heavy volumes.
 "drugs, generics, drug, pharma, pharmaceuticals, medicines, tablets, capsules, healthcare, IPR")
premium
Some major Western concerns about India’s patent framework are the definitions of inventions and provisions for compulsory licensing
SMS Pharmaceuticals has surged 20% to Rs 87.60 on BSE in intra-day trade after the successful inspection of Telengana plant by Japanese regulator.
The company successfully completed inspection by Pharmaceuticals and Medical Devices Agency (PMDA) Japanese Authorities for the manufacturing facility-Unit II, located in Hyderabad – Telangana.
The inspection was done during the period July 25 – 27. The inspection was focussed on general GMP (Good Manufacturing Practice) inspection of the site. The inspection has been concluded with no critical/major observation.
At 02:52 PM; the stock was up 16% to Rs 84.35 on BSE, as compared to 0.95% rise in the S&P BSE Sensex. The trading volumes on the counter jumped multiple-fold with a combined 1.2 million shares changed hands on BSE and NSE so far.
The company successfully completed inspection by Pharmaceuticals and Medical Devices Agency (PMDA) Japanese Authorities for the manufacturing facility-Unit II, located in Hyderabad – Telangana.
The inspection was done during the period July 25 – 27. The inspection was focussed on general GMP (Good Manufacturing Practice) inspection of the site. The inspection has been concluded with no critical/major observation.
At 02:52 PM; the stock was up 16% to Rs 84.35 on BSE, as compared to 0.95% rise in the S&P BSE Sensex. The trading volumes on the counter jumped multiple-fold with a combined 1.2 million shares changed hands on BSE and NSE so far.